Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Company News

CSPC's AlaMab gets rights to UT Health San Antonio's mAbs

Paul Bonanos
June 27, 2017 9:18 PM UTC

The University of Texas' UT Health San Antonio granted the AlaMab Therapeutics Inc. subsidiary of CSPC Pharmaceutical Group Ltd. (HKSE:1093; Pink:CHPTY) exclusive, worldwide rights to IP covering two protein channel mAbs. AlaMab's license covers the mAbs' therapeutic and diagnostic use to treat breast cancer bone metastasis and spinal cord injury. Both are in preclinical testing.

The university is to receive total license fees of $4.5 million and is eligible for up to $109.5 million in additional milestones, plus royalties...

Get Unlimited Access
Continue reading with a free trial.
Start a Free TrialLog In
Or Purchase This Article

BCIQ Company Profiles

Cspc Pharmaceutical Group Ltd.

University of Texas